Horwitz Prize to be shared by Tony Hunter, Anthony Pawson

November 30, 2004

NEW YORK, Nov. 30 - Columbia University has announced that its 2004 Louisa Gross Horwitz Prize will be shared by two researchers whose scientific contributions to the understanding of signal transduction - the transfer of information within and between cells - have led to drug therapies that halt the spread of cancer.

The awardees are Tony Hunter, American Cancer Society professor of molecular and cell biology at the Salk Institute for Biological Studies in San Diego, and Anthony Pawson, senior investigator and director of research at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, and university professor of medical genetics and microbiology at the University of Toronto.

The researchers will receive the award in February 2005 in recognition of their discoveries in understanding protein-tyrosine phosphorylation. This process of molecular signals within and between cells has led to the development of drugs for halting cancer cell proliferation and has potential for other significant therapies.

"This creative work by Hunter and Pawson has given us new insight into cell metabolism that goes beyond the original and historical concepts of the role of phosphate," said David Hirsh, executive vice president for research at Columbia University. "It is most appropriate that they will receive the Horwitz Prize, an award known for its prescience in recognizing major scientific contributions."

Gerald Fischbach, executive vice president and dean of Columbia University Medical Center, said, "Drs. Hunter and Pawson have laid the foundation for an extraordinarily important field of study that is now leading to new breakthroughs in clinical treatment of disease."

Awarded annually since its inception in 1967, the Louisa Gross Horwitz Prize recognizes exceptional accomplishments in biological and biochemical research. The prize was named after the mother of Columbia benefactor S. Gross Horwitz. Mrs. Horwitz was the daughter of former American Medical Association President and surgery textbook author Samuel David Gross.

Protein phosphorylation is the addition of a phosphate group to a protein, in order to provide an on-off switch for molecular signals within and between cells. For example, many enzymes and receptors are turned "on" or "off" through phosphorylation and dephosphorylation. These signals are crucial in the development of tissues, immune system responses and hormone action.

Tyrosine is one of the 20 amino acids found in proteins. In 1979, Hunter discovered that a phosphate could be attached to tyrosine in proteins, a significant advancement in understanding how cell growth is regulated. Tyrosine kinases - the enzymes that add phosphates to proteins - tell cells when to multiply in a controlled manner; when overactive, however, they can drive the continuous proliferation of cancer cells.

This discovery, a major advance in the field of signal transduction, opened the door to further study of cell growth in a variety of diseases. The research ultimately led to the development of a new generation of targeted drugs that block the action of tyrosine kinases and can stop the proliferation of some types of cancer cells. Gleevec®, a groundbreaking oral treatment for one form of leukemia, is successful because it blocks the wayward tyrosine kinase that drives this particular cancer.

Pawson's work has provided essential insight into how cells signal each other, and has had a broad impact throughout biomedical research. In 1986, he identified protein modules that recognize specific phosphorylated tyrosine residues and established that molecular protein interactions control signal transduction.
Columbia University in the City of New York, founded in 1754 as King's College by royal charter of King George II of England, is the oldest institution of higher learning in the state of New York and the fifth oldest in the United States.

Columbia University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.